Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic

Site
Bethesda

Protocol Number
AM0010-301

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer